Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Open Label, Single Dose Study To Investigate The Pharmacokinetics, Safety and Tolerability Of Dalbavancin In Hospitalized Children Aged 3 Months to 11 Years Receiving Standard Intravenous Anti-Infective Treatment For Bacterial Infections

NCT01946568 is registered in ClinicalTrials.gov with Durata Therapeutics Inc., an affiliate of Allergan plc as lead sponsor.

NCT NCT01946568
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01946568 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Open Label, Single Dose Study To Investigate The Pharmacokinetics, Safety and Tolerability Of Dalbavancin In Hospitalized Children Aged 3 Months to 11 Years Receiving Standard Intravenous Anti-Infective Treatment For Bacterial Infections
Lead sponsor
Durata Therapeutics Inc., an affiliate of Allergan plc
Phase
Phase 1
Overall status
Completed
Start date
June 30, 2013
Completion date
April 30, 2015
Enrollment
36 (estimated)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

bacterial infections.